Epilepsy Market Research by Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), by Diagnosis & Treatment (Diagnosis & Treatment), by End-use (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others), Industry Size, Growth Opportunity, Technology, Latest Trends and Regional Analysis – Global Forecast till 2023
Global Epilepsy Market is showing a substantial market growth and its valuation can quite easily reach a valuation mark of USD 9,509.2 million by 2023, and it would also display 8.20% CAGR during the time period of 2018 and 2023, which as per the study of Market Research Future (MRFR) can be termed as forecast period.
Click the link to get a Sample Copy of the Report: https://www.marketresearchfuture.com/sample_request/7730
Market Overview
Epilepsy can be classed as a major neurological disorder where the brain activity becomes abnormal and triggers unusual behavior and sensations. The disorder is discernible in young children and young adults and requires proper attention in time before it can impact the body in an adverse way.
The regional market is showing ample scope where a high prevalence of the disease can inspire growth in diverse regions.
In addition, the global market would benefit from the presence of countries in the African region where various global bodies are trying to launch initiatives to assist local doctors in curbing the diseases. However, poor economies can detract the growth rate.
Major Competitive Landscape:
MRFR’s analysis of various companies to get close to factors that can decipher the market growth and assist in the implementation of several market strategies. The recording of these moves can inspire a better understanding of the global scenario. Companies playing a significant role in providing thrust to the market are –
Pfizer Inc. (U.S.)
NeuroPace Inc. (U.S.)
Johnson & Johnson Services Inc. (U.S.)
UCB SA (Belgium)
GlaxoSmithKline PLC (U.K.)
LivaNova PLC (U.K.)
Medtronic PLC (Ireland)
Eisai Co. Ltd. (Japan)
Novartis AG (Switzerland)
GW Pharmaceuticals PLC (U.K.)
Abbott Laboratories (U.S.)
and Others.
In November 2019, NICE cleared the use of Epidyolex, a drug with cannabis in it. This is the first time a drug for cannabis got cleared to treat epilepsy in children.
14 LIST OF TABLES
TABLE 1 MARKET SYNOPSIS
TABLE 2 PRIMARY INTERVIEWS
TABLE 3 GLOBAL EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 4 GLOBAL EPILEPSY MARKET, FOR EPILEPSY DRUG-RESISTANT/ INTRACTABLE EPILEPSY, BY REGION 2015–2023 (USD MILLION)
TABLE 5 GLOBAL EPILEPSY MARKET, FOR OTHERS, BY REGION 2015–2023 (USD MILLION)
TABLE 6 GLOBAL EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 7 GLOBAL EPILEPSY MARKET, FOR DIAGNOSIS, BY REGION, 2015-2023 (USD MILLION)
TABLE 8 GLOBAL EPILEPSY MARKET, FOR TREATMENT, BY REGION, 2015-2023 (USD MILLION)
TABLE 9 GLOBAL EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
Continued…
Browse Full Report: https://www.marketresearchfuture.com/reports/epilepsy-market-7730
Epilepsy Market Segmentation:
The report on the epilepsy market encompasses segments like by condition, diagnosis & treatment, and end-use to facilitate an easy understanding of the market and gauge well how the regional market would shape up in the coming years.
By condition, the market report on epilepsy covers epilepsy drug-resistant/intractable epilepsy and others.
By diagnosis and treatment, the market report on epilepsy includes diagnosis and treatment. The diagnosis segment can be sub-segmented into blood tests, imaging devices, and others. The treatment segment includes neurostimulation devices, anti-epileptic drugs, ketogenic diet, brain surgery, and others.
By end-users, the epilepsy market can include clinics, hospitals, diagnostic centers, ambulatory surgical centers, and others.
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Rising Prevalence Of Epilepsy Amongst The Geriatric Population
5.2.2 Increasing Cases Of Brain Injuries Due To Road Accidents
5.2.3 Rising Neurological Disorders
5.2.4 Increasing Research Funding In Epilepsy
5.3 Restraints
5.3.1 Loss Of Patent Protection For Branded Drugs
5.3.2 High Costs Associated With The Treatment Of Epilepsy
5.4 Opportunities
5.4.1 Entering Developing Economies
Inquire For Discount at: https://www.marketresearchfuture.com/check-discount/7730
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312